Clinical Trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Study acronym: INAVO123
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).
Protocol Amendment History 3 changes
notable Trial sites expanded: 227 -> 232 locations 2026-07-03
notable Trial sites expanded: 219 -> 226 locations 2026-05-05
notable Trial sites expanded: 210 -> 219 locations 2026-04-04
Trial Details
NCT Number NCT06790693
Lead Sponsor Hoffmann-La Roche
Conditions Breast Cancer
Enrollment 450 participants
Start Date 2025-04-09
Primary Completion 2032-05-30 (estimated)
Study Completion 2032-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02